ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Friendly User's Guide for the Timing of Nutritional Supplements

The Health Benefits of Manuka Honey

Increase Your Magnesium Intake

Vitamin D supplementation could ease IBS symptoms

Top Tips to Boost Your Immunity

11 Amazing Health Benefits of Using Baking Soda

Nicotinamide riboside shows promise for treatment of Alzheimer’s disease

Exercise, calcium, vitamin D, and other factors linked with fewer injurious falls

Vitamin D3 Is a Powerhouse for Your Heart

Curcumin Supplementation May Impart Long-Term Cognitive Benefits

 
Print Page
Email Article

Phase III Clinical Trials in Progress for New Rheumatoid Arthritis Treatment

  [ Not Yet Rated ]   [ Discuss This Article ]
By News Release • www.ProHealth.com • February 4, 2000


SUMMARY: phase III trials have been initiated to test the fully human anti-TNF monoclonal antibody D2E7 for the treatment of rheumatoid arthritis. D2E7 belongs to a new class of medicines that neutralize TNF (tumour necrosis factor alpha). TNF is a cell communications protein that plays a role in the immune system. In rheumatoid arthritis, TNF accumulates disproportionately in the joints and initiates an inflammatory response that causes swelling, pain and joint damage, often rendering the patient unable to perform daily activities. Anti-TNF drugs neutralize this reaction by blocking the chemical message sent from cell to cell that results in joint inflammation and swelling. Essentially, D2E7 captures TNF and interrupts the process that can lead to the symptoms of RA.

MELBOURN, England, Feb. 4 /PRNewswire/ -- Cambridge Antibody Technology (CAT) today announces that BASF Pharma has initiated phase III trials of the fully human anti-TNF monoclonal antibody D2E7 in rheumatoid arthritis. D2E7 belongs to a new class of medicines that neutralize TNF (tumour necrosis factor alpha). TNF is a cell communications protein that
plays a role in the immune system. In rheumatoid arthritis, TNF accumulates disproportionately in the joints and initiates an inflammatory response that causes swelling, pain and joint damage,
often rendering the patient unable to perform daily activities. Anti-TNF drugs neutralize this reaction by blocking the chemical message sent from cell to cell that results in joint inflammation and swelling. Essentially, D2E7 captures TNF and interrupts the process
that can lead to the symptoms of RA.

D2E7 was initially isolated and optimized as part of a research collaboration between BASF Pharma and CAT. BASF Pharma is solely responsible for the pre-clinical/clinical development of the product and its marketing, pending successful completion of the pivotal studies and regulatory approval.

Dr. David Chiswell, Chief Executive of CAT, commented, “D2E7 is the first fully human monoclonal antibody to enter phase III trials. Taken together with the three other human monoclonal antibodies developed with CAT's technology also in clinical trials, it cements CAT's technology as the leading technology platform in the development of fully human antibodies as drugs.”

Dr. Thorlef Spickschen, Head of BASF Pharma, commented, “The decision to start clinical phase III underlines our confidence in the clinical phase II data recently presented at the Annual Scientific Meeting of the American College of Rheumatology in Boston. At the same time, it demonstrates our strong commitment to the area of immunology.”
Rheumatoid arthritis is one of the most common forms of arthritis, affecting more than six million people worldwide.

SOURCE: Cambridge Antibody Technology Group



Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ Energy NADH™ 12.5mg Ultra EPA  - Fish Oil


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get Energized with Malic Acid & Magnesium
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

The Crucial Role CoQ10 Plays in Fibromyalgia and ME/CFS The Crucial Role CoQ10 Plays in Fibromyalgia and ME/CFS
The Guaifenesin Story: A centuries-old bark extract used for clearing the airways – now key to a popular FM symptom-reversal protocol The Guaifenesin Story: A centuries-old bark extract used for clearing the airways – now key to a popular FM symptom-reversal protocol
Nutrients to Combat the Modern Stress Epidemic Nutrients to Combat the Modern Stress Epidemic
Undenatured Type II Collagen - Chicken Soup for Your Joints Undenatured Type II Collagen - Chicken Soup for Your Joints
"It's Not Easy Being Green" - But It Is Healthy

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2018 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map